… Furthermore, non-oncogenic HPV are responsible for the majority of genital warts. Two
prophylactic HPV vaccines are available, … Human papillomavirus vaccines—immune responses …

… National incidence of genital warts in Denmark has declined since the implementation of
a national human papillomavirus vaccination program with a quadrivalent vaccine, with …

… quadrivalent HPV vaccine were effective against genital warts in our population. Moreover,
with low vaccine coverage the incidence of genital warts decreased only in the vaccinated. …

… HPV-related disease. We provide nationwide, real-world data on the risk of genital warts (GWs)
after <3 vaccine doses… papillomavirus vaccine doses. IRs are presented for girls initiating …

… In this study, we describe the ongoing population effect of the quadrivalent human
papillomavirus vaccination programme on genital warts in Australian patients five years after the …

Objectives To assess the effectiveness of the HPV vaccines in preventing genital warts (GW)
in women aged 14–23 years and to estimate the incidence of GW in the whole population …

… of a prophylactic quadrivalent human papillomavirus (HPV) vaccine have been met in …
infection with HPV types 16 and 18 and ∼90% of genital warts are caused by HPV types 6 …

… the impact of human papillomavirus vaccine in the recurrence of ano-genital warts. … HPV
vaccine in preventing the relapse of ano-genital warts. The results suggest that HPV vaccination …

… of a nonavalent HPV vaccination for treatment of genital warts because the vaccine may
be beneficial as an alternative noninvasive treatment of recalcitrant genital warts. However, …

… cervical cancer plus genital warts, or … of the vaccine, the effect of information framing (’cervical
cancer’ versus ’cervical cancer plus genital warts’) on intention to receive the HPV vaccine …